Skip to main content

Halozyme Therapeutics, Inc. (HALO) Stock Analysis

Recovery setup

Buy WaitVALUE-TRAP 2/5Moderate Confidence

Healthcare · Biotechnology

Wait for pullback to $65.77. At $69.00 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $65.77 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Counterparty: Roche; Thin upside margin: 7.8%.

Halozyme Therapeutics licenses its ENHANZE drug delivery platform (rHuPH20 enzyme) to 13 pharmaceutical partners including Roche, Janssen, Takeda, AbbVie, Pfizer, and argenx, earning royalties on 10 approved commercial products plus milestones and bulk rHuPH20 sales. Revenue is... Read more

$69.00+12.4% A.UpsideScore 6.6/10#4 of 157 Biotechnology
QualityF-score8 / 9FCF yield2.80%
Entry $65.77(Atr Pullback Sticky)Stop $60.16Target $74.34(analyst − 13%)A.R:R 0.8:1Setup A.R:R 1.8:1
Analyst target$85.44+23.8%9 analysts
$74.34our TP
$69.00price
$85.44mean
$57
$96

Wait for pullback to $65.77. At $69.00 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $65.77 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Counterparty: Roche; Thin upside margin: 7.8%. Chart setup: Death cross but MACD improving, RSI 65. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.22, quality 9.0/10, growth 9.1/10). Score 6.6/10, moderate confidence.

Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 76d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.

Val7.5Qual9.0Grw9.1Mom6.1Sent6.8Ins3.4Peer5.2Tech4.4Risk4.36.6OVERALL

Recent Developments — Halozyme Therapeutics, Inc.

Material events (past 30 days)

  • Apr 30, 2026 MEDIUM Item 5.02: Darren Snellgrove appointed CFO effective June 8, 2026, succeeding Interim CFO David Ramsay who moves to advisory role. Snellgrove was previously CFO of J&J's Pharmaceutical sector and most recently VP Investor Relations at J&J.

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
V7 flight-to-quality bonus: +0.5 (Q=9.0 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (3/4)
Risks
Concentration risk — Counterparty: Roche
Thin upside margin: 7.8%
Leverage penalty (D/E 9.9): -1.5

Key Metrics

P/E (TTM)24.1
P/E (Fwd)7.0
Mkt Cap$8.2B
EV/EBITDA10.5
Profit Mgn23.1%
ROE99.4%
Rev Growth42.2%
Beta0.88
DividendNone
Rating analysts15

Quality Signals

Piotroski F8/9MoatWideCompounder✓

Options Flow

P/C0.78neutral
IV45%normal
Max Pain$45-34.8% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHcounterpartyRoche
    10-K Item 1: 'We currently earn royalties from the sales of ten commercial products including sales of five commercial products from the Roche collaboration'

Material Events(8-K, last 90d)

  • 2026-04-30Item 5.02MEDIUM
    Darren Snellgrove appointed CFO effective June 8, 2026, succeeding Interim CFO David Ramsay who moves to advisory role. Snellgrove was previously CFO of J&J's Pharmaceutical sector and most recently VP Investor Relations at J&J.
    SEC filing →
  • 2026-03-12Item 5.02MEDIUM
    David Ramsay appointed Interim CFO effective March 23, 2026; formerly served as Company's CFO 2003-2009 and 2013-2015. No permanent CFO successor named at time of filing.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 ceiling hits

GatesA.R:R 0.8 < 1.5@spotMomentum 6.1>=5.5Insider activity: OKNo SEC red flagsNEWS EVENTS NONE RECENTEARNINGS PROXIMITY 76d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
65 · Neutral
↑ 20D MA↑ 50D MA↓ 200D MADEATH CROSSSupport $62.38Resistance $73.89

Price Targets

$60
$66
$74
A.Upside+7.7%
A.R:R0.8:1
Setup A.R:R (at entry)1.8:1

Position Sizing

ConvictionHigh conviction
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Reward/Risk 0.8:1 at current price — below 1.5:1 minimum

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-08-04 (76d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is HALO stock a buy right now?

Wait for pullback to $65.77. At $69.00 the A.R:R is 0.8:1 — below the 1.5:1 minimum for BUY_NOW. Engine's entry $65.77 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Counterparty: Roche; Thin upside margin: 7.8%. Chart setup: Death cross but MACD improving, RSI 65. Growth is cheap relative to earnings, but the chart hasn't confirmed yet (PEG 0.22, quality 9.0/10, growth 9.1/10). Target $74.34 (+7.7%), stop $60.16 (−14.7%), Setup A.R:R 1.8:1. Score 6.6/10, moderate confidence.

What is the HALO stock price target?

Take-profit target: $74.34 (+12.4% upside). Target $74.34 (+7.7%), stop $60.16 (−14.7%), Setup A.R:R 1.8:1. Stop-loss: $60.16.

What are the risks of investing in HALO?

Concentration risk — Counterparty: Roche; Thin upside margin: 7.8%; Leverage penalty (D/E 9.9): -1.5.

Is HALO overvalued or undervalued?

Halozyme Therapeutics, Inc. trades at a P/E of 24.1 (forward 7.0). TrendMatrix value score: 7.5/10. Verdict: Buy (Wait for Entry).

What do analysts say about HALO?

15 analysts cover HALO with a consensus score of 3.8/5. Average price target: $85.

What does Halozyme Therapeutics, Inc. do?Halozyme Therapeutics licenses its ENHANZE drug delivery platform (rHuPH20 enzyme) to 13 pharmaceutical partners...

Halozyme Therapeutics licenses its ENHANZE drug delivery platform (rHuPH20 enzyme) to 13 pharmaceutical partners including Roche, Janssen, Takeda, AbbVie, Pfizer, and argenx, earning royalties on 10 approved commercial products plus milestones and bulk rHuPH20 sales. Revenue is concentrated with Roche contributing five of the ten commercial products generating royalties. The company also develops auto-injector devices and proprietary products.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · ARGX (argenx SE) · ADMA (ADMA Biologics Inc) · GLPG (Galapagos NV)